The global varicose veins treatment market size was valued at USD 1.25 billion in 2025 and is projected to grow from USD 1.33 billion in 2026 to USD 2.28 billion by 2035, at a CAGR of 6.2% from 2026 to 2035. North America dominated the market, accounting for a revenue share of 45.0% in 2025.
The global varicose veins treatment market is experiencing steady growth, driven by the rising prevalence of chronic venous disorders, aging populations, sedentary lifestyles, obesity, and increased awareness of vascular health. Once considered primarily a cosmetic issue, varicose veins are now widely recognized as a progressive medical condition that can lead to chronic venous insufficiency, pain, swelling, skin changes, and venous ulcers if left untreated.
The market has witnessed a significant shift from traditional vein stripping surgeries to minimally invasive procedures such as endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and ultrasound-guided foam sclerotherapy. These advanced treatments offer shorter recovery times, reduced complications, and improved patient outcomes, making them the preferred choice among healthcare providers and patients. Continued technological innovations, expanding outpatient vascular centers, favorable reimbursement policies, and increasing healthcare investments in emerging economies are further supporting market growth. In addition, growing demand for both therapeutic and cosmetic vein treatments is expanding the patient base, positioning the global varicose veins treatment market for sustained long-term expansion.
AI and ML are revolutionizing the global varicose veins treatment industry by enhancing diagnostic accuracy and driving personalized care. Advanced machine learning algorithms analyze ultrasound, MRI, and thermal images to detect subtle venous abnormalities, significantly reducing human error and workflow times. During minimally invasive procedures, AI computer vision provides real-time surgical guidance, ensuring precise catheter placement and energy delivery. AI models leverage patient data to anticipate recurrence risks and tailor specific treatments to individual anatomies, which ultimately improves overall clinical outcomes.
| Report Coverage | Details |
| Market Size in 2026 | USD 1.33 Billion |
| Market Size by 2035 | USD 2.28 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 6.2% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Type, End-Use, Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Medtronic; Lumenis Be Ltd.; AngioDynamics; Sciton; Quanta System; intros Medical Laser GmbH; Alma lasers; Dornier MedTech; Theraclion |
Rising Prevalence of Chronic Venous Disorders and Aging Population
The growing incidence of chronic venous disorders, supported by an aging global population, is a key driver of the varicose veins treatment market. Older adults are more susceptible to weakened vein valves and reduced vascular elasticity, increasing the risk of varicose veins and chronic venous insufficiency. Additionally, obesity, sedentary lifestyles, prolonged standing, pregnancy, and genetic factors continue to raise disease prevalence. As awareness and diagnosis improve, healthcare providers are expanding vascular care services and adopting minimally invasive treatment technologies to meet rising patient demand.
High Cost of Advanced Minimally Invasive Procedures
The high cost of advanced treatment technologies remains a major challenge for market growth. Procedures such as endovenous laser therapy and radiofrequency ablation require expensive equipment, disposable devices, and specialized physician training, increasing overall treatment costs. In many developing countries, limited reimbursement and insurance coverage—particularly for procedures considered cosmetic—reduce patient access, while smaller healthcare facilities often continue relying on conventional surgical methods due to budget constraints.
Expansion of Outpatient Vein Treatment Centers
The rapid growth of outpatient vein treatment centers presents a significant opportunity for the market. Modern minimally invasive procedures can be performed under local anesthesia with same-day discharge, offering greater convenience and lower healthcare costs. As demand for efficient, cost-effective vascular care increases, healthcare providers are investing in specialized vein clinics equipped with advanced laser, radiofrequency, and ultrasound technologies. This trend is expected to create substantial opportunities for medical device manufacturers, healthcare providers, and digital health solution developers.
Why did the Injection sclerotherapy segment dominate the Global Varicose Veins Treatment market?
The injection sclerotherapy segment is driven by the favorable procedure benefits, including reduced bruising, no scarring, and immediate same-day patient mobility. The technological advancements in safer, more effective chemical sclerosants have improved success rates. The increasing disease prevalence of chronic venous insufficiency, fueled by sedentary lifestyles, obesity, and an aging demographic, is driving a steady influx of global procedural volume.
How did the endovenous ablation segment expected to hold the fastest-growing Global Varicose Veins Treatment market in the coming years?
The endovenous ablation segment is driven by the minimally invasive, outpatient-friendly nature that significantly reduces recovery times and scarring. The shift towards ambulatory settings is supported by technological advancements, including non-thermal techniques, while favorable reimbursement policies accelerate global adoption. Growing insurance coverage for minimally invasive venous therapies, particularly across North America and Europe, continues to accelerate market adoption.
Why did the hospitals segment dominate the Global Varicose Veins Treatment market?
The hospitals segment is driven by the advanced infrastructure and specialized expertise of highly trained vascular surgeons and interventional radiologists who seamlessly perform both traditional open surgeries and advanced minimally invasive ablations. Their institutional framework provides comprehensive, multi-disciplinary care pathways that integrate cardiology, radiology, and dermatology to handle severe comorbidities.
How did the ambulatory surgical centers segment expected to hold the fastest-growing Global Varicose Veins Treatment market in the coming years?
The ambulatory surgical centers segment is driven by the expanded insurance coverage and favorable reimbursement policies for outpatient and ambulatory procedures, which are accelerating the shift away from inpatient surgical wards. Miniaturized and advanced radiofrequency equipment allows for safer, non-thermal, and minimally invasive treatments that can be securely executed in specialized ambulatory settings without the need for intensive care infrastructure.
Why did the North American region account for the largest share in the Global Varicose Veins Treatment market?
North America is driven by an advanced healthcare infrastructure featuring a dense network of specialized vascular centers and outpatient vein clinics. The robust industry presence from leading global device manufacturers ensures immediate regional availability of cutting-edge ablation technologies. The rising geriatric population and high obesity rates contribute to securing steady revenue growth. High patient awareness regarding vascular health and visible symptoms, which consistently drives early diagnosis and rapid clinical intervention.
U.S. Global Varicose Veins Treatment Market Trends
The U.S. significant outpatient shift away from hospitals toward specialized vein clinics and ambulatory surgical centers, propelling growth. The rapid technological integration is introducing advanced non-thermal, non-tumescent systems, such as medical glues, alongside major investments in AI-powered diagnostics mapping by industry leaders. Covering this trend optimizes patient convenience and safety while securing robust, long term expansion across the global vascular care therapeutics sector.
Why did the Europe region become the fastest-growing global veterinary point-of-care (PoC) Diagnostics Market during the forecast period?
In Europe, the strict regional antibiotic stewardship guidelines legally obligate veterinarians to perform culture-guided testing before prescribing, directly boosting the sales of real-time point-of-care tests. A strong, widespread emphasis on animal welfare and preventive medicine ensures rapid clinic adoption of advanced infectious disease and hormone analysis tools to optimize early disease management.
U.K Global Varicose Veins Treatment Market Trends
U.K's experiencing a rapid shift toward endogenous laser therapy and radiofrequency ablation, offering patients significantly faster recovery times and reduced post-operative pain. Despite this transition, injection sclerotherapy maintains its overall dominance as the most widely performed medical and cosmetic procedure for smaller veins due to its exceptional cost-effectiveness. The structural coverage limits and long public waitlists are driving a massive surge in patients opting for independent specialty vein clinics and private ambulatory surgical centers.
Why Did Asia Pacific Hold A Notable Share in the Global Varicose Veins Treatment Market?
Asia Pacific’s massive patient pool and rapidly aging demographics drastically boost procedural volumes for chronic venous insufficiency across nations such as China, India, and Japan. This expanding disease burden is met by a definitive consumer shift toward minimally invasive outpatient treatments like EVLT and sclerotherapy, which offer minimal scarring and shorter recovery times. The rising disposable incomes among an expanding middle class are driving high demand for cosmetic vein solutions, a trend heavily capitalized on by prominent regional medical tourism hubs.
China Global Varicose Veins Treatment Market Trends
China’s shift toward minimally invasive endogenous ablation devices such as laser and radiofrequency, which represent the fastest therapeutic segment. The dominance of outpatient settings, where specialized vascular clinics and ambulatory surgical centers (ASCs) optimize care delivery.
Medtronic drives the market with its proprietary non-thermal, non-tumescent VenaSeal Closure System, which uses a medical adhesive to permanently seal diseased veins. Additionally, the company provides the widely used ClosureFast procedure, a minimally invasive radiofrequency thermal therapy that redirects blood flow and enables rapid patient recovery.
AngioDynamics dominates the endovenous laser therapy (EVLT) space through its flagship VenaCure EVLT System, utilizing 1470nm water-specific lasers to effectively obliterate varicose veins. Their proprietary NeverTouch gold-tip fibers maximize ultrasound visibility while preventing direct contact with the vein wall, which drastically reduces post-operative pain and bruising.
biolitec AG specializes in advanced, minimally invasive laser treatments featuring their flagship ELVeS Radial product family and Leonardo diode lasers.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has varicose veins treatment market.
By Type
By End-use
By Region
Varicose Veins Treatment Market
Download Sample
Request Customization
Request Customization
Download Sample